



CERTOLIZUMAB PEGOL solution for injection (Cimzia®) for Plaque Psoriasis

G
R
E
Y

The Pan Mersey Area Prescribing Committee does not currently recommend the prescribing of CERTOLIZUMAB PEGOL solution for injection (Cimzia®) for the treatment of Plaque Psoriasis.

Certolizumab has recently been granted a further license extension and is now indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.^[1]

This recommendation will be reviewed when the NICE TA is published. This is expected to be in April 2019.

In the meantime, clinicians should continue to follow local and national guidance on the treatment of plaque psoriasis:

- > Pan Mersey Area Prescribing Committee: [Sequential Use of Biological Agents in the Management of Psoriasis in Adults](#) (last updated June 2018)
- > National Institute for Health and Care Excellence: [Psoriasis Pathway](#) (last updated June 2018)

Reference:

1. UCB Pharma Limited. Summary of Product Characteristics: [Cimzia 200 mg solution for injection in pre-filled pen](#), 26 June 2018. Accessed online 28 August 2018.

Note: Patients who are not eligible for treatment under this statement may be considered on an individual basis where their GP or consultant believes exceptional circumstances exist that warrant deviation from the rule of this policy. In this situation, follow locally defined processes.